183 related articles for article (PubMed ID: 19052474)
1. Urinary oxidative stress markers closely reflect the efficacy of candesartan treatment for diabetic nephropathy.
Yoshida S; Hashimoto T; Kihara M; Imai N; Yasuzaki H; Nomura K; Kiuchi Y; Tamura K; Ishigami T; Hirawa N; Toya Y; Kitamura H; Umemura S
Nephron Exp Nephrol; 2009; 111(1):e20-30. PubMed ID: 19052474
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy.
Ogawa S; Mori T; Nako K; Kato T; Takeuchi K; Ito S
Hypertension; 2006 Apr; 47(4):699-705. PubMed ID: 16505207
[TBL] [Abstract][Full Text] [Related]
3. Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice.
Liao J; Kobayashi M; Kanamuru Y; Nakamura S; Makita Y; Funabiki K; Horikoshi S; Tomino Y
J Nephrol; 2003; 16(6):841-9. PubMed ID: 14736011
[TBL] [Abstract][Full Text] [Related]
4. A novel diabetes mellitus mouse model, MAFA-deficient and beta cell-specific MAFK-overexpressing hybrid transgenic mice, developed severe diabetic nephropathy and improved with TCV-116 (candesartan cilexetil) treatment.
Fujita A; Yoh K; Shimohata H; Morito N; Ojima M; Okamura M; Takahashi S; Yamagata K
Exp Anim; 2012; 61(1):49-57. PubMed ID: 22293672
[TBL] [Abstract][Full Text] [Related]
5. Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice.
Fan Q; Liao J; Kobayashi M; Yamashita M; Gu L; Gohda T; Suzuki Y; Wang LN; Horikoshi S; Tomino Y
Nephrol Dial Transplant; 2004 Dec; 19(12):3012-20. PubMed ID: 15574998
[TBL] [Abstract][Full Text] [Related]
6. [Effects of angiotensin II type 1 receptor blocker on islet of diabetic db/db mice].
Shao JQ; Iwashita N; Du H; Wang YY; Zhao M; Wang J; Watada H; Kawamori R
Zhonghua Nei Ke Za Zhi; 2007 Apr; 46(4):306-10. PubMed ID: 17637271
[TBL] [Abstract][Full Text] [Related]
7. Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy.
Sato A; Tabata M; Hayashi K; Saruta T
Clin Exp Nephrol; 2003 Sep; 7(3):215-20. PubMed ID: 14586718
[TBL] [Abstract][Full Text] [Related]
8. Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons.
Kuwabara T; Mori K; Mukoyama M; Kasahara M; Yokoi H; Saito Y; Yoshioka T; Ogawa Y; Imamaki H; Kusakabe T; Ebihara K; Omata M; Satoh N; Sugawara A; Barasch J; Nakao K
Kidney Int; 2009 Feb; 75(3):285-94. PubMed ID: 19148153
[TBL] [Abstract][Full Text] [Related]
9. Telmisartan attenuates diabetic nephropathy by suppressing oxidative stress in db/db mice.
Sato-Horiguchi C; Ogawa D; Wada J; Tachibana H; Kodera R; Eguchi J; Nakatsuka A; Terami N; Shikata K; Makino H
Nephron Exp Nephrol; 2012; 121(3-4):e97-e108. PubMed ID: 23307263
[TBL] [Abstract][Full Text] [Related]
10. ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study.
Böger RH; Schwedhelm E; Maas R; Quispe-Bravo S; Skamira C
Vasc Med; 2005 Jul; 10 Suppl 1():S97-102. PubMed ID: 16444875
[TBL] [Abstract][Full Text] [Related]
11. Urinary Smad1 is a novel marker to predict later onset of mesangial matrix expansion in diabetic nephropathy.
Mima A; Arai H; Matsubara T; Abe H; Nagai K; Tamura Y; Torikoshi K; Araki M; Kanamori H; Takahashi T; Tominaga T; Matsuura M; Iehara N; Fukatsu A; Kita T; Doi T
Diabetes; 2008 Jun; 57(6):1712-22. PubMed ID: 18285555
[TBL] [Abstract][Full Text] [Related]
12. Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice.
Fujii M; Inoguchi T; Maeda Y; Sasaki S; Sawada F; Saito R; Kobayashi K; Sumimoto H; Takayanagi R
Kidney Int; 2007 Aug; 72(4):473-80. PubMed ID: 17568784
[TBL] [Abstract][Full Text] [Related]
13. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
[TBL] [Abstract][Full Text] [Related]
14. Increased urinary type IV collagen marks the development of glomerular pathology in diabetic d/db mice.
Cohen MP; Lautenslager GT; Shearman CW
Metabolism; 2001 Dec; 50(12):1435-40. PubMed ID: 11735089
[TBL] [Abstract][Full Text] [Related]
15. Reduction of circulating superoxide dismutase activity in type 2 diabetic patients with microalbuminuria and its modulation by telmisartan therapy.
Fujita H; Sakamoto T; Komatsu K; Fujishima H; Morii T; Narita T; Takahashi T; Yamada Y
Hypertens Res; 2011 Dec; 34(12):1302-8. PubMed ID: 21814206
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin receptor blockade in diabetic renal disease--focus on candesartan.
García Donaire JA; Ruilope LM
Diabetes Res Clin Pract; 2007 May; 76 Suppl 1():S22-30. PubMed ID: 17339065
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin II receptor blocker provides pancreatic beta-cell protection independent of blood pressure lowering in diabetic db/db mice.
Shao JQ; Iwashita N; Du H; Wang YT; Wang YY; Zhao M; Wang J; Watada H; Kawamori R
Acta Pharmacol Sin; 2007 Feb; 28(2):246-57. PubMed ID: 17241528
[TBL] [Abstract][Full Text] [Related]
18. Prevention of diabetic nephropathy by treatment with astaxanthin in diabetic db/db mice.
Naito Y; Uchiyama K; Aoi W; Hasegawa G; Nakamura N; Yoshida N; Maoka T; Takahashi J; Yoshikawa T
Biofactors; 2004; 20(1):49-59. PubMed ID: 15096660
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy.
Ogawa S; Mori T; Nako K; Ito S
Hypertens Res; 2008 Jun; 31(6):1147-55. PubMed ID: 18716362
[TBL] [Abstract][Full Text] [Related]
20. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Bilous R; Chaturvedi N; Sjølie AK; Fuller J; Klein R; Orchard T; Porta M; Parving HH
Ann Intern Med; 2009 Jul; 151(1):11-20, W3-4. PubMed ID: 19451554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
